Want to see AU:NUC full AI Analyst Report?
NUC Stock Chart & Stats
AU$0.12
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.12
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.07 - AU$0.23
Previous CloseN/A
Volume11.15K
Average Volume (3M)7.76K
Market Cap
AU$13.33M
Enterprise ValueAU$16.50
Total Cash (Recent Filing)AU$3.11M
Total Debt (Recent Filing)AU$529.14K
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding156,818,770
10 Day Avg. Volume3,027
30 Day Avg. Volume7,761
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.82
Price to Sales (P/S)0.89
P/FCF Ratio-5.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)AU$28.30M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthA 45%+ top-line increase signals durable market demand for the Olli probiotic line and successful distribution execution. Sustained revenue growth helps absorb fixed costs, supports scale economics, and creates a runway for margin recovery and product investment over the next 2–6 months.
Low LeverageConservative leverage preserves financial flexibility while the business scales and repairs profitability. Low debt reduces refinancing risk and interest burden, giving management scope to fund inventory, marketing or strategic initiatives without immediate solvency pressure.
Branded Omnichannel DistributionOwning a branded product (Olli) sold through both wholesale and direct online channels provides diversified revenue streams and stronger consumer relationships. This omnichannel model supports repeat purchase patterns and higher-margin DTC opportunities that can sustain growth and margin improvement long-term.
Bears Say
Negative Cash FlowPersistent negative operating and free cash flows indicate the business is burning cash to fund growth and operations. That constrains reinvestment, increases likelihood of external funding needs, and limits the company's ability to capitalize on distribution or marketing opportunities without diluting equity or increasing leverage.
Ongoing Losses & Negative ROEContinued negative EBIT and ROE show the company is not yet converting sales into shareholder returns. Persistent unprofitability erodes equity value, restricts retained earnings for reinvestment, and raises the bar for management to demonstrate structural margin fixes to achieve sustainable profitability.
Limited Scale / Small TeamA small headcount and presence focused on Australia plus 'select' international markets suggests limited scale versus larger consumer-health competitors. That can constrain negotiating power, distribution reach, and R&D/marketing bandwidth, making margin expansion and international rollouts harder over the medium term.
Nuchev Pty Ltd News
NUC FAQ
What was Nuchev Pty Ltd’s price range in the past 12 months?
Nuchev Pty Ltd lowest share price was AU$0.07 and its highest was AU$0.23 in the past 12 months.
What is Nuchev Pty Ltd’s market cap?
Nuchev Pty Ltd’s market cap is AU$13.33M.
When is Nuchev Pty Ltd’s upcoming earnings report date?
Nuchev Pty Ltd’s upcoming earnings report date is Aug 27, 2026 which is in 35 days.
How were Nuchev Pty Ltd’s earnings last quarter?
Nuchev Pty Ltd released its earnings results on Feb 24, 2026. The company reported -AU$0.02 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Nuchev Pty Ltd overvalued?
According to Wall Street analysts Nuchev Pty Ltd’s price is currently Overvalued.
Does Nuchev Pty Ltd pay dividends?
Nuchev Pty Ltd does not currently pay dividends.
What is Nuchev Pty Ltd’s EPS estimate?
Nuchev Pty Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nuchev Pty Ltd have?
Nuchev Pty Ltd has 156,818,770 shares outstanding.
What happened to Nuchev Pty Ltd’s price movement after its last earnings report?
Nuchev Pty Ltd reported an EPS of -AU$0.02 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Nuchev Pty Ltd?
Currently, no hedge funds are holding shares in AU:NUC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nuchev Pty Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.34%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.10%
Trailing 12-Months
Company Description
Nuchev Pty Ltd
Nuchev Limited functions as a specialized health and nutrition company, responsible for the production, marketing, and distribution of infant formula and various nutritional items derived from goat milk. Its products are sold to consumers across Australia, China, and Vietnam. The firm offers a range of options under its Oli6 brand, including toddler nutrition, powdered goat milk, and general health and wellness goods. These products can be purchased through both conventional retail outlets and online e-commerce platforms. Nuchev Limited was established in 2013 and maintains its corporate headquarters in Melbourne, Australia.
Technical Analysis
Noumi Limited
―
Australian Dairy Nutritionals Group
―
Bubs Australia Ltd.
―
Nutritional Growth Solutions Ltd.
―
Clover Corporation Limited
―